ORIC Pharmaceuticals Announces First Subject Dosed in Phase 1 Clinical Study of Novel GR Antagonist with Planned Development for Oncology

Friday, October 27, 2017 Cancer News
Email Print This Page Comment bookmark
Font : A-A+

SOUTH SAN FRANCISCO, Calif., Oct. 27, 2017 /PRNewswire/ -- ORIC Pharmaceuticals ("ORIC"), a privately held oncology company

focused on the discovery and development of drugs to address treatment resistant cancers, announced today that the first subject in a Phase 1a clinical study has been dosed with ORIC-101, a potent small molecule inhibitor of the glucocorticoid receptor
(GR). Activation of GR allows tumor cells to circumvent current cancer therapies, and suppresses the immune system's ability to recognize tumor cells.  

ORIC-101 was discovered and tested by ORIC's internal research team, based in part on early work by Dr. Charles Sawyers, one of ORIC's founders, that linked GR to anti-androgen resistance in castration-resistant prostate cancer.

The Phase 1a study of ORIC-101, currently underway in the United States, is designed to assess the safety, pharmacokinetics and pharmacodynamics of ORIC-101 in healthy volunteers. "The ORIC-101 program is the result of our research to characterize the role of the glucocorticoid receptor axis in therapy resistance, and to target it with a small molecule therapeutic," said Valeria Fantin, PhD, ORIC's Chief Scientific Officer.  "As we take this first step into the clinic, we look forward to understanding how ORIC-101 may improve oncology therapy in the future."  

ORIC is continuing to assess activity of ORIC-101 across a wide range of cancer models. The results of those studies and of the current Phase 1a will inform future development of ORIC-101.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals is a privately held cancer therapy company focused on the discovery and development of drugs targeting treatment resistant cancers. ORIC was founded by Drs. Charles Sawyers MD and Scott Lowe PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has also assembled a strong leadership team, a highly experienced scientific team, and a Board with extensive experience in both drug development and financing. The company launched in 2014 and is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Foresite Capital, and Kravis Investment Partners. ORIC is headquartered in South San Francisco, California. 

For more information, please contact:

Krys Corbett[email protected]http://oricpharma.com/

 

View original content:http://www.prnewswire.com/news-releases/oric-pharmaceuticals-announces-first-subject-dosed-in-phase-1-clinical-study-of-novel-gr-antagonist-with-planned-development-for-oncology-300544631.html

SOURCE ORIC Pharmaceuticals



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store